ABT-700 shows preclinical activities in blocking both HGF-dependent and HGF-independent c-Met signaling, inducing apoptosis and suppressing tumor growth in cancers with amplified MET. Collectively, the attributes of ABT-700 coupled with early signs of activity in a phase 1 clinical trial support investigation of this antibody, as monotherapy and in combination, in malignancies characterized by aberrant activation of c-Met signaling including cancers harboring MET amplification. Here, HGF is linked to cancer.